Hints and tips:
...Franz Humer Senior Independent Director, Chair of the Remuneration Committee, LetterOne, Zurich, Switzerland...
...Letter in response to this editorial comment: LetterOne ‘follows strict payout rules at all times’ / From Franz Humer, Senior Independent Director, Chair of the Remuneration Committee, LetterOne, Zurich...
...Franz Humer, former chair of Diageo and Roche, joined the board in March....
...Dr Franz Humer, who was chairman of Roche until 2014 and worked with Mr Miels in Asia, described him as “friendly, tough and charming” and a “quick learner who learns from his mistakes”....
...Franz Humer, former chief executive of Roche, and Lord John Hutton, the former defence secretary, are also among its non-executive team....
...He will join Diageo’s board next month as a non-executive director before taking over as chairman from Dr Franz Humer on January 1 next year, the group behind Guinness stout and Johnnie Walker whisky said...
...The handover from veteran chairman Franz Humer will mark a decisive end to an era for a distiller whose present business has been largely shaped by Paul Walsh, the former chief executive who was succeeded...
...Some critics mutter about a lack of pharmaceuticals experience on the Roche board, particularly since Franz Humer, a company veteran, stepped down as chairman last year to be replaced by Christoph Franz,...
...Ensuring Ms Mahlan gets some operational grit under her fingernails is just good succession planning by chairman Franz Humer....
...Roche’s former chairman, Franz Humer, said last January that a deal with the US group was now “definitely off the table”. Shares in Roche were up 0.3 per cent at SFr262.5 in midday trading in Zürich....
...Europe risks losing investment in research and development because of the reluctance of cash-strapped governments to pay for innovative medicines, the chairman of Roche has warned Franz Humer, who steps...
...Roche saw its own changing of the guard this week when Mr Humer was succeeded by Christoph Franz, outgoing chief executive of Lufthansa....
...Mr Franz will succeed Franz Humer, who said in March he would not stand for re-election....
...His comments came just two weeks after Christoph Franz was named to replace Franz Humer as chairman of Roche, and a month after Jörg Reinhardt took over from Daniel Vasella as chairman of Novartis....
...That triggered a stand-off with his counterpart Franz Humer, who is stepping down next year. Mr Reinhardt hints at warmer co-operation ahead....
...Franz Humer, 68, Roche’s chairman, told investors at the annual general meeting on Tuesday he would step down in 2014, and the board had agreed that his successor would follow his lead by not recombining...
...Roche, the Swiss pharmaceutical group, said Mr Voser – who sits on its board – would not take over as chairman after Franz Humer stands down next year....
...Roche chairman Franz Humer said that his company was no longer interested in buying Illumina, telling a Swiss newspaper that an acquisition was “definitely off the table” and helping push the US genetics...
...Franz Humer, the chairman, has announced he will step down over the coming year, although the group is not yet expected to reveal the name of a successor....
...Franz Humer, chairman of Roche, said it was “possible” to trim 30-50 per cent off drug development costs through better co-ordination, design and implementation of clinical trials....
...Along with Joseph Jimenez, Novartis’s chief executive, and Franz Humer, the chairman of Roche, the cash payments of the top executives at the two Swiss drug groups exceed those of all their peers....
...Humer, Roche’s chairman....
...The third-biggest US bank by assets also announced on Thursday that it intended to appoint to its board Franz Humer, chairman of Roche, and Joan Spero, a former government official and American Express executive...
...The offer came alongside release of a new letter from Franz Humer, Roche’s chairman, to Jay Flatley, US-based Illumina’s president and chief executive, in which he argued the Swiss group’s move had been...
...In a letter to Franz Humer, Roche’s chairman, Jay Flatley, Illumina’s president and chief executive, said the offer, valuing the US diagnostics group at about $6.7bn, “dramatically undervalues Illumina and...
International Edition